Breast adenoid cystic carcinoma (AdCC) is a rare subtype of triple negative breast cancer. Two morphologic variants are described, namely classic AdCC (C-AdCC) and solid basaloid (SB-AdCC). Recent studies have shown that the SB-AdCC variant has significantly worse prognosis than C-AdCC. Due to the rarity of SB-AdCC, no standard recommendations are available for its management. Data on the use and benefit of chemotherapy in patients with SB-AdCC are sparse and the response to neoadjuvant chemotherapy has not been reported. We present the clinical and pathologic findings of a patient with SB-AdCC treated with neoadjuvant chemotherapy who achieved a remarkable pathologic response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372162PMC
http://dx.doi.org/10.1038/s41523-022-00469-zDOI Listing

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
12
adenoid cystic
8
cystic carcinoma
8
response neoadjuvant
8
sb-adcc
5
solid-basaloid variant
4
variant adenoid
4
carcinoma breast
4
breast complete
4
complete response
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!